AstraZeneca 2021 semi-annual report: The Chinese market grew by 21%, and Ochinib sold for US$2.45 billion worldwide

On July 29, AstraZeneca released its 2021 interim report

In addition to the contribution of the Covid-19 vaccine, its revenue in the first half of the year increased by 14% to 14.

Sales in China increased by 21% in the first half of the year

Sub-regional perspective, emerging markets in the first half revenue of $ 5.

China currently accounts for 59% of AstraZeneca’s total revenue in emerging markets, and its revenue reached US$3.

In the first half of this year, many AstraZeneca products have made great progress in China:

June 2021, AstraZeneca's PARP inhibitor Ola Palley ( Lynpa rz A ) approved in China, BRCA mutation treatment of advanced prostate cancer (mCRPC), become approved for advanced prostate cancer first PARP Inhibitor

In June 2021, AstraZeneca and Hutchison Pharmaceuticals jointly developed Syvotinib ( Orpat h ys ) obtained conditional approval for the treatment of NSCLC in China

July 2021, AstraZeneca degree cutting Li You monoclonal antibody ( Imfinz i ) the approval by the State Food and Drug Administration to expand the indications for the treatment of first-line treatment of extensive stage small cell lung cancer (ES-SCLC)

The tumor segment increased by 19%, and many products showed double-digit growth

In terms of segments, the anti-tumor business's anti-tumor segment revenue was US$6.
36 billion , a year-on-year increase of 19%
.
The total revenue of the respiratory and immunology segment reached 2.
97 billion US dollars, an increase of 11% year-on-year
.
Biopharmaceuticals revenue was US$5.
7 billion , an increase of 15% year-on-year, with the remainder being the new crown vaccine and other drugs
.
Among them, the new crown vaccine revenue is 1.
169 billion U.
S.
dollars
.

The anti-tumor segment's revenue in the first half of the year was 6.
36 billion US dollars, an increase of 19% year-on-year.
The top three products Tagrisso (Teresa), Imfinzi (duvaliumab) and Lynparza all maintained double-digit rapid growth
.

Among them, the third-generation EGFR-targeted drug Tagrisso (Teresa) had a revenue of US$ 2.
454 billion in the first half of the year, an increase of 22% year-on-year; the PD-L1 monoclonal antibody duvalimab (Imfinzi) had a revenue of US$1.
16 billion in the first half of the year.
A year-on-year increase of 22%; PARP inhibitor Lynp arza ( Lynp arza ) revenue in the first half of the year was 1.
13 billion US dollars, a year-on-year increase of 19%.
On May 20, 2020, AstraZeneca and Merck announced that Lynparza was approved by the FDA for use in the United States.
Homologous recombination repair (HRR) gene mutations in patients with metastatic castration-resistant prostate cancer (mCRPC)
.

In addition, the hypoglycemic drug Farxiga (dapagliflozin) had revenue of US$1.
359 billion, an increase of 60% year-on-year
.
In May last year, dapagliflozin was approved by the US FDA for a new indication for adult patients with heart failure (HFrEF) with reduced ejection fraction (with or without type 2 diabetes) to reduce cardiovascular (CV) deaths And the risk of hospitalization for heart failure
.
Respiratory drug was Symbicort (budesonide formoterol inhalation) revenue of $ 1.
371 billion, down 5%
.

summary

Multinational pharmaceutical companies generally supplement pipelines and new products through mergers and acquisitions and high R&D investment to maintain growth
.
AstraZeneca is no exception.
At the end of December last year, AstraZeneca acquired Alexion Pharmaceuticals for US$39 billion, acquiring Alexion Pharmaceuticals’ complement technology R&D platform and rare disease R&D capabilities, and further enriching and improving the coverage of AstraZeneca’s product pipeline.
Enhance AstraZeneca's industry position in the field of rare diseases
.

In the first half of the year, AstraZeneca's research and development expenses reached US$3.
542 billion, an increase of more than 20%, mainly for its new crown vaccine, drug and anti-tumor pipeline research and development investment
.